Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,267 across all filing types
Latest filing 2020-05-08 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
As required under Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we furnish herewith a Certificate issued by the Practicing Company Secretary ....
Regulatory Filings
2020-05-08 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2020-05-07 English
We are enclosing herewith Certificate dated April 10, 2020 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming ....
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, issued by the Registrar and Transfer Agent confirming compliance with dematerialization procedures for the period 01.03.2020 to 31.03.2020. It is addressed to stock exchanges and signed by the company secretary. The document is short (3786 characters) and primarily a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. It is not an announcement of a report but a regulatory compliance certificate. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance certificates and miscellaneous regulatory documents.
2020-04-13 English
Updates
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, issued by the Registrar and Transfer Agents confirming compliance with dematerialization and securities listing requirements for the period 01.03.2020 to 31.03.2020. It is addressed to stock exchanges and signed by the company secretary. The document is short (3786 characters) and primarily a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. It is not an announcement of a report publication but a regulatory compliance certificate. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance document that does not fit other specific categories.
2020-04-13 English
This is to certify that, Integrated Registry Management Services Private Limited are the Company's Registrar and Transfer Agents and that all activities in relation to the share transfer ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) certifying that the company's Registrar and Transfer Agents (Integrated Registry Management Services Private Limited) maintain all activities related to share transfers. It references compliance with Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The content is a certification letter rather than a financial report or announcement of financial results. The document length is 4227 characters, which is relatively short and primarily contains a certification statement. There is no financial data, no report attached or referenced as being published, and no detailed financial or management information. Therefore, this document fits best under Regulatory Filings (RNS) as it is a regulatory compliance certification letter.
2020-04-10 English
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Tejas B Trivedi
Regulatory Filings
2020-03-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.